Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Monitoring NT-proBNP in Patients with Diabetes

Diabetes Care; ePub 2018 May 30; Jarolim, et al

Serial monitoring of N-terminal B-type natriuretic peptide (NT-proBNP) in patients with type 2 diabetes (T2D) and ischemic heart disease may be useful for identifying patients at highest risk for heart failure (HF), a recent study suggests. NT-proBNP was measured at baseline and 6 months. Cardiovascular (CV) death or hospitalization for HF was the primary end point. Researchers found:

  • A graded relationship between increasing baseline and 6-month NT-proBNP concentration and the incidence of major CV events was observed.
  • After adjusting for potential confounders, NT-proBNP at baseline was independently associated with the development of major CV events, especially hospitalization for HF.
  • Patients with persistently high NT-proBNP or developed high NT-proBNP at 6 months were at a significantly higher risk for CV death/HF than those in whom NT-proBNP remained low at both time points.
  • Treatment with a DPP-4 inhibitor did not meaningfully alter NT-proBNP concentrations.


Jarolim P, White WB, Cannon CP, Gao Q, Morrow DA. Serial measurement of natriuretic peptides and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE Trial. [Published online ahead of print May 30, 2018]. Diabetes Care. doi:10.2337/dc18-0109.